Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating mocertatug rezetecan Mo-Rez in treating endometrial cancer EC compared to standard chemotherapy options. The study aims to understand how well Mo-Rez works and how safe and tolerable it is for participants, including comparing side effects between Mo-Rez and standard treatments. This is a phase 3 randomized, open-label study focusing on treatment after prior platinum-based chemotherapy and immunotherapy. Participants will receive either mocertatug rezetecan or standard of care chemotherapy, which includes paclitaxel or doxorubicin, based on the investigators choice. The study uses a parallel design to compare these treatments directly. Treatment and assessments will continue for up to about 97 weeks for primary outcomes, with longer follow-up for secondary outcomes up to approximately 156 weeks. Throughout the study, participants will undergo multiple evaluations, including tumor response assessments by blinded independent central review and investigator assessments. Researchers will monitor progression-free survival, overall survival, treatment side effects, and quality of life using specialized questionnaires. Laboratory tests, vital signs, ECGs, and antibody measurements against the study drug will also be performed. The total participation time may extend over several years to capture long-term outcomes and safety data.
Actively Recruiting
Healthy Volunteer
This research investigates the use of artificial intelligence AI to assist in contouring during radiation treatment for breast cancer patients. The trial compares AI-assisted contouring using the in-house LOCATOR software with fully manual contouring done by radiation oncologists. The study aims to evaluate whether AI-assisted contouring matches the quality of manual contouring and whether it can save oncologists time. It is a multicenter, phase II randomized controlled trial focusing on contour quality and efficiency. Participants are randomly assigned in a 31 ratio to either AI-assisted contouring or manual contouring groups. The AI model is initially trained on data from previous breast cancer cases and is updated regularly as more patients participate. In the AI-assisted group, contours are generated by the LOCATOR software and then manually reviewed and adjusted by oncologists. The manual group receives the standard care with contours created entirely by oncologists. During the study, researchers assess contour quality using the MD Anderson Contouring Grade Scale and various geometric and dosimetric measures. They also evaluate time savings, clinician-reported toxicity, patient-reported quality of life, and economic costs. Follow-up includes acute and late toxicity and quality of life assessments over 18 months to 5 years. Participant involvement includes contouring procedures, toxicity monitoring, questionnaires, and outcome evaluations over the study period.
Actively Recruiting
This research is focused on patients with acute severe brain injuries, such as those caused by stroke, traumatic injury, or oxygen loss after cardiac arrest, who require mechanical ventilation. It evaluates whether giving a single dose of a commonly used antibiotic soon after intubation can prevent infections in the airways and lungs, known as pneumonia, which is a common complication in these patients. The study aims to improve survival and recovery chances by preventing these infections early. Participants are randomly assigned to receive either a single intravenous dose of 2 grams of ceftriaxone diluted in at least 200 mL of 0.9% sodium chloride or a placebo an intravenous infusion of 0.9% sodium chloride without ceftriaxone shortly after intubation. This is a double-blind trial, meaning neither participants nor researchers know who receives the antibiotic or placebo. The treatment is given once shortly after the breathing tube is inserted. During the study, participants will be monitored for 90 days to measure overall survival and for 180 days to assess functional outcomes related to brain injury recovery. Researchers will collect data on survival rates, neurological function, length of mechanical ventilation, need for reintubation or tracheostomy, and other related health measures. The study also monitors safety and evaluates if antibiotic use affects outcomes and antibiotic resistance over time.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.
Actively Recruiting
Researchers are evaluating the drug opevesostat in comparison to alternative hormonal therapies abiraterone acetate or enzalutamide for adults with metastatic castration-resistant prostate cancer mCRPC who have previously been treated with next-generation hormonal agents and taxane-based chemotherapy. This phase 3, randomized, open-label study aims to determine if opevesostat improves overall survival in participants both with and without androgen receptor ligand binding domain mutations. Participants are randomly assigned to receive either opevesostat 5 mg orally twice daily combined with dexamethasone 1.5 mg once daily and fludrocortisone acetate 0.1 mg once daily, or alternative therapies consisting of abiraterone 1000 mg once daily with prednisone 5 mg twice daily, or enzalutamide 160 mg once daily. Hydrocortisone is provided as rescue medication as needed. Treatment continues until disease progression. During the study, participants undergo regular assessments including monitoring overall survival, radiographic progression-free survival, time to subsequent therapies, response duration, pain progression, prostate-specific antigen levels, and safety evaluations for adverse events. The study may last up to approximately 54 months for key outcome measures, with ongoing monitoring to assess treatment effects and participant safety throughout the trial.